How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 320-336

  Malhaire, Hélène ^a,b   Gimel, Jean Christophe ^a,b   Roger, Emilie ^a,b   Benoît, Jean Pierre ^a,b   Lagarce, Frédéric ^a,b,c  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Mucus interaction; Nanoparticle; Protein and peptide drugs; Protein corona; Specific surface area

Indexed keywords

BIOCHEMISTRY; BODY FLUIDS; NANOPARTICLES; PEPTIDES; SPECIFIC SURFACE AREA;

INTESTINAL EPITHELIUM; KEY CHARACTERISTICS; MUCUS INTERACTION; ORAL ADMINISTRATION; ORAL BIOAVAILABILITIES; PEPTIDE DRUGS; PROTEIN CORONAS; SOURCE OF ENERGY;

PROTEINS;

CYCLOSPORIN; DESMOPRESSIN; DRUG ADDITIVE; EXCIPIENT; MUCOADHESIVE PARTICLE; MUCUS PENETRATING PARTICLE; NANOCARRIER; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; DRUG CARRIER; NANOPARTICLE; PEPTIDE;

ACTIVE MUCODIFFUSION; BACK DIFFUSION; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DESIGN; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; ENDOCYTOSIS; GASTROINTESTINAL TRACT; HUMAN; INTESTINE EPITHELIUM; INTESTINE MUCOSA; MOLECULAR DYNAMICS; MOLECULAR STABILITY; MUCOADHESION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PASSIVE MUCODIFFUSION; PERMEABILITY BARRIER; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SURFACE PROPERTY; TISSUE INTERACTION; VISCOELASTICITY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; HUMANS; INTESTINAL MUCOSA; NANOPARTICLES; PEPTIDES;

EID: 84964573678     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.03.011     Document Type: Review

References (261)

1. [1] Ramesan, R.M., Sharma, C.P., Recent advances in the oral delivery of insulin. Recent Pat. Drug Deliv. Formul. 8 (2014), 155–159.
2. [2] Luo, Y.Y., Xiong, X.Y., Tian, Y., Li, Z.L., Gong, Y.C., Li, Y.P., A review of biodegradable polymeric systems for oral insulin delivery. Drug Deliv., 2015, 1–10.
3. [3] Lopes, M.A., Abrahim, B.A., Seica, R., Veiga, F., Rodrigues, C.R., Ribeiro, A.J., Intestinal uptake of insulin nanoparticles: facts or myths?. Curr. Pharm. Biotechnol. 15 (2014), 629–638.
4. [4] Lopes, M.A., Abrahim, B.A., Cabral, L.M., Rodrigues, C.R., Seiça, R.M.F., de Baptista Veiga, F.J., Ribeiro, A.J., Intestinal absorption of insulin nanoparticles: contribution of M cells. Nanomedicine 10 (2014), 1139–1151.
5. [5] Fonte, P., Araújo, F., Silva, C., Pereira, C., Reis, S., Santos, H.A., Sarmento, B., Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol. Adv., 2015.
6. [6] Kubota, M., Yamasaki, Y., Sekiya, M., Kubota, M., Morishima, T., Kishimoto, M., Kawamori, R., Shichiri, M., Kamada, T., Portal insulin delivery is superior to peripheral delivery in handling of portally delivered glucose. Metabolism 45 (1996), 150–154.
7. [7] Chen, M.-C., Sonaje, K., Chen, K.-J., Sung, H.-W., A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32 (2011), 9826–9838.
8. [8] Canavan, J.P., Flecknell, P.A., New, J.P., Alberti, K.G.M.M., Home, P.D., The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM. Diabetologia 40 (1997), 1125–1134.
9. [9] Allémann, E., Leroux, J.-C., Gurny, R., Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Deliv. Rev. 34 (1998), 171–189.
10. [10] Chaturvedi, K., Ganguly, K., Nadagouda, M.N., Aminabhavi, T.M., Polymeric hydrogels for oral insulin delivery. J. Control. Release 165 (2013), 129–138.
11. [11] Schilling, R.J., Mitra, A.K., Intestinal mucosal transport of insulin. Int. J. Pharm. 62 (1990), 53–64.
12. [12] Orive, G., Hernández, R.M., Gascón, A.R.g., Domı́nguez-Gil, A., Pedraz, J.L., Drug delivery in biotechnology: present and future. Curr. Opin. Biotechnol. 14 (2003), 659–664.
13. [13] Chabner, D.E., The Language of Medicine. 2013, Saunders/Elsevier.
14. [14] Brown, T.A., Rapid Review Physiology: With STUDENT CONSULT Online Access. 2011, Elsevier Health Sciences.
15. [15] Bakhru, S.H., Furtado, S., Morello, A.P., Mathiowitz, E., Oral delivery of proteins by biodegradable nanoparticles. Adv. Drug Deliv. Rev. 65 (2013), 811–821.
16. [16] Atuma, C., Strugala, V., Allen, A., Holm, L., The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 280 (2001), G922–G929.
17. [17] Bischoff, S.C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.D., Serino, M., Tilg, H., Watson, A., Wells, J.M., Intestinal permeability—a new target for disease prevention and therapy. BMC Gastroenterol., 14, 2014, 189.
18. [18] Kim, Y.S., Erickson, R.H., Role of peptidases of the human small intestine in protein digestion. Gastroenterology 88 (1985), 1071–1073.
19. [19] Berg, J.M., Tymoczko, J.L., Stryer, L., Biochemistry. fifth ed., 2002, International Version, W. H. Freeman.
20. [20] Peterson, L.W., Artis, D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14 (2014), 141–153.
21. [21] Johansson, M.E., Sjovall, H., Hansson, G.C., The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 352–361.
22. [22] Desai, M.P., Labhasetwar, V., Amidon, G.L., Levy, R.J., Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13 (1996), 1838–1845.
23. [23] des Rieux, A., Pourcelle, V., Cani, P.D., Marchand-Brynaert, J., Préat, V., Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65 (2013), 833–844.
24. [24] Choonara, B.F., Choonara, Y.E., Kumar, P., Bijukumar, D., du Toit, L.C., Pillay, V., A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol. Adv. 32 (2014), 1269–1282.
25. [25] Oberdorster, G., Maynard, A., Donaldson, K., Castranova, V., Fitzpatrick, J., Ausman, K., Carter, J., Karn, B., Kreyling, W., Lai, D., Olin, S., Monteiro-Riviere, N., Warheit, D., Yang, H., Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol., 2, 2005, 8.
26. [26] Florence, A.T., Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discov. Today Technol. 2 (2005), 75–81.
27. [27] Abbott, L.C., Maynard, A.D., Exposure assessment approaches for engineered nanomaterials. Risk Anal. 30 (2010), 1634–1644.
28. [28] Bleeker, E.A., de Jong, W.H., Geertsma, R.E., Groenewold, M., Heugens, E.H., Koers-Jacquemijns, M., van de Meent, D., Popma, J.R., Rietveld, A.G., Wijnhoven, S.W., Cassee, F.R., Oomen, A.G., Considerations on the EU definition of a nanomaterial: science to support policy making. Regul. Toxicol. Pharmacol. 65 (2013), 119–125.
29. [29] Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond.) 5 (2010), 287–306.
30. [30] Warheit, D.B., Sayes, C.M., Reed, K.L., Swain, K.A., Health effects related to nanoparticle exposures: environmental, health and safety considerations for assessing hazards and risks. Pharmacol. Ther. 120 (2008), 35–42.
31. [31] Tran, C.L., Buchanan, D., Cullen, R.T., Searl, A., Jones, A.D., Donaldson, K., Inhalation of poorly soluble particles. II. Influence of particle surface area on inflammation and clearance. Inhal. Toxicol. 12 (2000), 1113–1126.
32. [32] Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., Dawson, K.A., Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 14265–14270.
33. [33] des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.J., Preat, V., Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006), 1–27.
34. [34] Brown, D.M., Wilson, M.R., MacNee, W., Stone, V., Donaldson, K., Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol. Appl. Pharmacol. 175 (2001), 191–199.
35. [35] Choc, M.G., Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune®. Int. J. Dermatol. 36 (1997), 1–6.
36. [36] Rembratt, A., Graugaard-Jensen, C., Senderovitz, T., Norgaard, J.P., Djurhuus, J.C., Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55–70 years. Eur. J. Clin. Pharmacol. 60 (2004), 397–402.
37. [37] Fjellestad-Paulsen, A., Höglund, P., Lundin, S., Paulsen, O., Pharmacokinetics of 1-deamino-8-d-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. 38 (1993), 177–182.
38. [38] Card, J.W., Magnuson, B.A., A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems. Am. J. Physiol. Gastrointest. Liver Physiol. 301 (2011), G956–G967.
39. [39] Zhang, Z.H., Zhang, Y.L., Zhou, J.P., Lv, H.X., Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. Int. J. Nanomedicine 7 (2012), 3333–3339.
40. [40] Sarmento, B., Martins, S., Ferreira, D., Souto, E.B., Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine 2 (2007), 743–749.
41. [41] Fonte, P., Nogueira, T., Gehm, C., Ferreira, D., Sarmento, B., Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv. Transl. Res. 1 (2011), 299–308.
42. [42] Jani, P.U., McCarthy, D.E., Florence, A.T., Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose. Int. J. Pharm. 86 (1992), 239–246.
43. [43] des Rieux, A., Fievez, V., Theate, I., Mast, J., Preat, V., Schneider, Y.J., An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 30 (2007), 380–391.
44. [44] Reineke, J.J., Cho, D.Y., Dingle, Y.-T., Morello, A.P., Jacob, J., Thanos, C.G., Mathiowitz, E., Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 13803–13808.
45. [45] Park, E.-J., Bae, E., Yi, J., Kim, Y., Choi, K., Lee, S.H., Yoon, J., Lee, B.C., Park, K., Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ. Toxicol. Pharmacol. 30 (2010), 162–168.
46. [46] Lomer, M.C., Grainger, S.L., Ede, R., Catterall, A.P., Greenfield, S.M., Cowan, R.E., Vicary, F.R., Jenkins, A.P., Fidler, H., Harvey, R.S., Ellis, R., McNair, A., Ainley, C.C., Thompson, R.P., Powell, J.J., Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur. J. Gastroenterol. Hepatol. 17 (2005), 377–384.
47. [47] Lomer, M.C., Harvey, R.S., Evans, S.M., Thompson, R.P., Powell, J.J., Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. Eur. J. Gastroenterol. Hepatol. 13 (2001), 101–106.
48. [48] Lomer, M.C., Kodjabashia, K., Hutchinson, C., Greenfield, S.M., Thompson, R.P., Powell, J.J., Intake of dietary iron is low in patients with Crohn's disease: a case–control study. Br. J. Nutr. 91 (2004), 141–148.
49. [49] Mahler, G.J., Esch, M.B., Tako, E., Southard, T.L., Archer, S.D., Glahn, R.P., Shuler, M.L., Oral exposure to polystyrene nanoparticles affects iron absorption. Nat. Nano 7 (2012), 264–271.
50. [50] Koeneman, B.A., Zhang, Y., Westerhoff, P., Chen, Y., Crittenden, J.C., Capco, D.G., Toxicity and cellular responses of intestinal cells exposed to titanium dioxide. Cell Biol. Toxicol. 26 (2010), 225–238.
51. [51] Hoet, P., Bruske-Hohlfeld, I., Salata, O., Nanoparticles—known and unknown health risks. J. Nanobiotechnol., 2, 2004, 12.
52. [52] Karasulu, H.Y., Ertan, G., Köse, T., Modeling of theophylline release from different geometrical erodible tablets. Eur. J. Pharm. Biopharm. 49 (2000), 177–182.
53. [53] Gratton, S.E.A., Ropp, P.A., Pohlhaus, P.D., Luft, J.C., Madden, V.J., Napier, M.E., DeSimone, J.M., The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. 105 (2008), 11613–11618.
54. [54] Williford, J.M., Santos, J.L., Shyam, R., Mao, H.Q., Shape control in engineering of polymeric nanoparticles for therapeutic delivery. Biomater. Sci. 3 (2015), 894–907.
55. [55] Kersey, F.R., Merkel, T.J., Perry, J.L., Napier, M.E., DeSimone, J.M., Effect of aspect ratio and deformability on nanoparticle extravasation through nanopores. Langmuir 28 (2012), 8773–8781.
56. [56] Truong, N.P., Whittaker, M.R., Mak, C.W., Davis, T.P., The importance of nanoparticle shape in cancer drug delivery. Expert Opin. Drug Deliv. 12 (2015), 129–142.
57. [57] Albanese, A., Tang, P.S., Chan, W.C.W., The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14 (2012), 1–16.
58. [58] Cosgrove, T., Colloid Science: Principles, Methods and Applications. 2010, Wiley.
59. [59] Kamaly, N., Xiao, Z., Valencia, P.M., Radovic-Moreno, A.F., Farokhzad, O.C., Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41 (2012), 2971–3010.
60. [60] Heller, W., Pugh, T.L., “Steric” stabilization of colloidal solutions by adsorption of flexible macromolecules. J. Polym. Sci. 47 (1960), 203–217.
61. [61] Huynh, N.T., Passirani, C., Saulnier, P., Benoit, J.P., Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm. 379 (2009), 201–209.
62. [62] Roger, E., Lagarce, F., Benoit, J.P., Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur. J. Pharm. Biopharm. 79 (2011), 181–188.
63. [63] Groo, A.C., Saulnier, P., Gimel, J.C., Gravier, J., Ailhas, C., Benoit, J.P., Lagarce, F., Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int. J. Nanomedicine 8 (2013), 4291–4302.
64. [64] Vonarbourg, A., Saulnier, P., Passirani, C., Benoit, J.P., Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface. Electrophoresis 26 (2005), 2066–2075.
65. [65] Tobio, M., Sanchez, A., Vila, A., Soriano, I.I., Evora, C., Vila-Jato, J.L., Alonso, M.J., The role of PEG on the stability in digestive fluids and in vivo fate of PEG–PLA nanoparticles following oral administration. Colloids Surf. B: Biointerfaces 18 (2000), 315–323.
66. [66] Feeney, O.M., Williams, H.D., Pouton, C.W., Porter, C.J., ‘Stealth’ lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. J. Control. Release 192 (2014), 219–227.
67. [67] Chaturvedi, K., Ganguly, K., Kulkarni, A.R., Rudzinski, W.E., Krauss, L., Nadagouda, M.N., Aminabhavi, T.M., Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles. Nanomedicine (Lond.) 10 (2015), 1569–1583.
68. [68] Calleja, P., Espuelas, S., Vauthier, C., Ponchel, G., Irache, J.M., Controlled release, intestinal transport, and oral bioavailablity of paclitaxel can be considerably increased using suitably tailored pegylated poly(anhydride) nanoparticles. J. Pharm. Sci. 104 (2015), 2877–2886.
69. [69] Yuan, H., Chen, C.Y., Chai, G.H., Du, Y.Z., Hu, F.Q., Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol. Pharm. 10 (2013), 1865–1873.
70. [70] Mohanraj, V.J., Barnes, T.J., Prestidge, C.A., Silica nanoparticle coated liposomes: a new type of hybrid nanocapsule for proteins. Int. J. Pharm. 392 (2010), 285–293.
71. [71] Andreani, T., de Souza, A.L., Kiill, C.P., Lorenzon, E.N., Fangueiro, J.F., Calpena, A.C., Chaud, M.V., Garcia, M.L., Gremiao, M.P., Silva, A.M., Souto, E.B., Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery. Int. J. Pharm. 473 (2014), 627–635.
72. [72] Andreani, T., Miziara, L., Lorenzon, E.N., de Souza, A.L., Kiill, C.P., Fangueiro, J.F., Garcia, M.L., Gremiao, P.D., Silva, A.M., Souto, E.B., Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: interactions with mucin and biomembrane models. Eur. J. Pharm. Biopharm. 93 (2015), 118–126.
73. [73] Yamamoto, A., Taniguchi, T., Rikyuu, K., Tsuji, T., Fujita, T., Murakami, M., Muranishi, S., Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11 (1994), 1496–1500.
74. [74] Su, F.Y., Lin, K.J., Sonaje, K., Wey, S.P., Yen, T.C., Ho, Y.C., Panda, N., Chuang, E.Y., Maiti, B., Sung, H.W., Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 33 (2012), 2801–2811.
75. [75] Bernkop-Schnürch, A., The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release 52 (1998), 1–16.
76. [76] Lueßen, H.L., de Leeuw, B.J., Pérard, D., Lehr, C.-M., de Boer, A.G., Verhoef, J.C., Junginger, H.E., Mucoadhesive polymers in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. Eur. J. Pharm. Sci. 4 (1996), 117–128.
77. [77] D.A. Hutton, J.P. Pearson, A. Allen, S.N. Foster, Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate, Clin. Sci. (Lond.), 78 (1990) 265-271.
78. [78] Lueßen, H., Verhoef, J.C., Borchard, G., Lehr, C.-M., de Boer, A.G., Junginger, H., Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res. 12 (1995), 1293–1298.
79. [79] Lee, V.H.L., Protease inhibitors and penetration enhancers as approaches to modify peptide absorption. J. Control. Release 13 (1990), 213–223.
80. [80] Bernkop-Schnurch, A., Marschutz, M.K., Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Pharm. Res. 14 (1997), 181–185.
81. [81] Welling, S.H., Hubálek, F., Jacobsen, J., Brayden, D.J., Rahbek, U.L., Buckley, S.T., The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm. 86 (2014), 544–551.
82. [82] Reseland, J.E., Holm, H., Jacobsen, M.B., Jenssen, T.G., Hanssen, L.E., Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. J. Nutr. 126 (1996), 634–642.
83. [83] Peppas, N.A., Huang, Y., Nanoscale technology of mucoadhesive interactions. Adv. Drug Deliv. Rev. 56 (2004), 1675–1687.
84. [84] Lai, S.K., Wang, Y.-Y., Wirtz, D., Hanes, J., Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 61 (2009), 86–100.
85. [85] Johansson, M.E., Ambort, D., Pelaseyed, T., Schutte, A., Gustafsson, J.K., Ermund, A., Subramani, D.B., Holmen-Larsson, J.M., Thomsson, K.A., Bergstrom, J.H., van der Post, S., Rodriguez-Pineiro, A.M., Sjovall, H., Backstrom, M., Hansson, G.C., Composition and functional role of the mucus layers in the intestine. Cell. Mol. Life Sci. 68 (2011), 3635–3641.
86. [86] Ensign, L.M., Cone, R., Hanes, J., Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64 (2012), 557–570.
87. [87] Bansil, R., Turner, B.S., Mucin structure, aggregation, physiological functions and biomedical applications. Curr. Opin. Colloid Interface Sci. 11 (2006), 164–170.
88. [88] Groo, A.C., Lagarce, F., Mucus models to evaluate nanomedicines for diffusion. Drug Discov. Today 19 (2014), 1097–1108.
89. [89] Park, J.W., Kim, S.J., Kwag, D.S., Kim, S., Park, J., Youn, Y.S., Bae, Y.H., Lee, E.S., Multifunctional delivery systems for advanced oral uptake of peptide/protein drugs. Curr. Pharm. Des. 21 (2015), 3097–3110.
90. [90] Luo, Y., Teng, Z., Li, Y., Wang, Q., Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr. Polym. 122 (2015), 221–229.
91. [91] Sosnik, A., Alginate particles as platform for drug delivery by the oral route: state-of-the-art. ISRN Pharm., 2014, 2014, 926157.
92. [92] Andrews, G.P., Laverty, T.P., Jones, D.S., Mucoadhesive polymeric platforms for controlled drug delivery. Eur. J. Pharm. Biopharm. 71 (2009), 505–518.
93. [93] Khafagy el, S., Morishita, M., Onuki, Y., Takayama, K., Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev. 59 (2007), 1521–1546.
94. [94] Grabovac, V., Guggi, D., Bernkop-Schnurch, A., Comparison of the mucoadhesive properties of various polymers. Adv. Drug Deliv. Rev. 57 (2005), 1713–1723.
95. [95] Bernkop-Schnurch, A., Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57 (2005), 1569–1582.
96. [96] Bernkop-Schnurch, A., Steininger, S., Synthesis and characterisation of mucoadhesive thiolated polymers. Int. J. Pharm. 194 (2000), 239–247.
97. [97] Khutoryanskiy, V.V., Advances in mucoadhesion and mucoadhesive polymers. Macromol. Biosci. 11 (2011), 748–764.
98. [98] Janes, K.A., Calvo, P., Alonso, M.J., Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47 (2001), 83–97.
99. [99] Hassan, E.E., Gallo, J.M., A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm. Res. 7 (1990), 491–495.
100. [100] Frohlich, E., The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine 7 (2012), 5577–5591.
101. [101] George, M., Abraham, T.E., Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review. J. Control. Release 114 (2006), 1–14.
102. [102] Jevprasesphant, R., Penny, J., Jalal, R., Attwood, D., McKeown, N.B., D'Emanuele, A., The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252 (2003), 263–266.
103. [103] Bernkop-Schnürch, A., Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm. 194 (2000), 1–13.
104. [104] Mourya, V.K., Inamdar, N.N., Chitosan-modifications and applications: opportunities galore. React. Funct. Polym. 68 (2008), 1013–1051.
105. [105] Bonengel, S., Bernkop-Schnürch, A., Thiomers—from bench to market. J. Control. Release 195 (2014), 120–129.
106. [106] Bernkop-Schnürch, A., Kast, C.E., Chemically modified chitosans as enzyme inhibitors. Adv. Drug Deliv. Rev. 52 (2001), 127–137.
107. [107] Sosnik, A., Neves, J. das, Sarmento, B., Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog. Polym. Sci. 39 (2014), 2030–2075.
108. [108] Sigurdsson, H.H., Kirch, J., Lehr, C.M., Mucus as a barrier to lipophilic drugs. Int. J. Pharm. 453 (2013), 56–64.
109. [109] Saettone, M.F., Monti, D., Torracca, M.T., Chetoni, P., Mucoadhesive ophthalmic vehicles: evaluation of polymeric low-viscosity formulations. J. Ocul. Pharmacol. 10 (1994), 83–92.
110. [110] Imperiale, J.C., Nejamkin, P., Del Sole, M.J., E.L. C, Sosnik, A., Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs. Biomaterials 37 (2015), 383–394.
111. [111] Maisel, K., Ensign, L., Reddy, M., Cone, R., Hanes, J., Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J. Control. Release 197 (2015), 48–57.
112. [112] Li, X., Guo, S., Zhu, C., Zhu, Q., Gan, Y., Rantanen, J., Rahbek, U.L., Hovgaard, L., Yang, M., Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 34 (2013), 9678–9687.
113. [113] Abdulkarim, M., Agulló, N., Cattoz, B., Griffiths, P., Bernkop-Schnürch, A., Borros, S.G., Gumbleton, M., Nanoparticle diffusion within intestinal mucus: three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles. Eur. J. Pharm. Biopharm. 97:Part A (2015), 230–238.
114. [114] Pereira de Sousa, I., Steiner, C., Schmutzler, M., Wilcox, M.D., Veldhuis, G.J., Pearson, J.P., Huck, C.W., Salvenmoser, W., Bernkop-Schnürch, A., Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles. Eur. J. Pharm. Biopharm. 97:Part A (2015), 273–279.
115. [115] Olmsted, S.S., Padgett, J.L., Yudin, A.I., Whaley, K.J., Moench, T.R., Cone, R.A., Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 81 (2001), 1930–1937.
116. [116] Lai, S.K., Wang, Y.-Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61 (2009), 158–171.
117. [117] Lai, S.K., O'Hanlon, D.E., Harrold, S., Man, S.T., Wang, Y.-Y., Cone, R., Hanes, J., Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. 104 (2007), 1482–1487.
118. [118] Saltzman, W.M., Radomsky, M.L., Whaley, K.J., Cone, R.A., Antibody diffusion in human cervical mucus. Biophys. J. 66 (1994), 508–515.
119. [119] Dünnhaupt, S., Kammona, O., Waldner, C., Kiparissides, C., Bernkop-Schnürch, A., Nano-carrier systems: strategies to overcome the mucus gel barrier. Eur. J. Pharm. Biopharm., 2015.
120. [120] Cone, R.A., Barrier properties of mucus. Adv. Drug Deliv. Rev. 61 (2009), 75–85.
121. [121] Macierzanka, A., Mackie, A.R., Bajka, B.H., Rigby, N.M., Nau, F., Dupont, D., Transport of particles in intestinal mucus under simulated infant and adult physiological conditions: impact of mucus structure and extracellular DNA. PLoS One, 9, 2014, e95274.
122. [122] Yudin, A.I., Human cervical mucus and its interaction with sperm: a fine-structural view. Biol. Reprod. 40 (1989), 661–671.
123. [123] Chretien, F.C., David, G., Temporary obstructive effect of human cervical mucus on spermatozoa throughout reproductive life: a scanning electron microscopic study. Eur. J. Obstet. Gynecol. Reprod. Biol. 8 (1978), 307–321.
124. [124] Crater, J.S., Carrier, R.L., Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol. Biosci. 10 (2010), 1473–1483.
125. [125] Mert, O., Lai, S.K., Ensign, L., Yang, M., Wang, Y.-Y., Wood, J., Hanes, J., A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J. Control. Release 157 (2012), 455–460.
126. [126] Wang, Y.Y., Lai, S.K., Suk, J.S., Pace, A., Cone, R., Hanes, J., Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew. Chem. Int. Ed. Eng. 47 (2008), 9726–9729.
127. [127] Groo, A.C., Mircheva, K., Bejaud, J., Ailhas, C., Panaiotov, I., Saulnier, P., Ivanova, T., Lagarce, F., Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules. Pharm. Res. 31 (2014), 1753–1765.
128. [128] Bourganis, V., Karamanidou, T., Samaridou, E., Karidi, K., Kammona, O., Kiparissides, C., On the synthesis of mucus permeating nanocarriers. Eur. J. Pharm. Biopharm. 97:Part A (2015), 239–249.
129. [129] Takatsuka, S., Morita, T., Koguchi, A., Horikiri, Y., Yamahara, H., Yoshino, H., Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Int. J. Pharm. 316 (2006), 124–130.
130. [130] Müller, C., Perera, G., König, V., Bernkop-Schnürch, A., Development and in vivo evaluation of papain-functionalized nanoparticles. Eur. J. Pharm. Biopharm. 87 (2014), 125–131.
131. [131] Amri, E., Mamboya, F., Papain, a plant enzyme of biological importance: a review. Am. J. Biochem. Biotechnol. 8 (2012), 99–104.
132. [132] Pereira de Sousa, I., Cattoz, B., Wilcox, M.D., Griffiths, P.C., Dalgliesh, R., Rogers, S., Bernkop-Schnürch, A., Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier. Eur. J. Pharm. Biopharm. 97:Part A (2015), 257–264.
133. [133] Wilcox, M.D., Van Rooij, L.K., Chater, P.I., Pereira de Sousa, I., Pearson, J.P., The effect of nanoparticle permeation on the bulk rheological properties of mucus from the small intestine. Eur. J. Pharm. Biopharm. 96 (2015), 484–487.
134. [134] Henke, M.O., Ratjen, F., Mucolytics in cystic fibrosis. Paediatr. Respir. Rev. 8 (2007), 24–29.
135. [135] Albanese, C.T., Cardona, M., Smith, S.D., Watkins, S., Kurkchubasche, A.G., Ulman, I., Simmons, R.L., Rowe, M.I., Role of intestinal mucus in transepithelial passage of bacteria across the intact ileum in vitro. Surgery 116 (1994), 76–82.
136. [136] Kollner, S., Dunnhaupt, S., Waldner, C., Hauptstein, S., Pereira de Sousa, I., Bernkop-Schnurch, A., Mucus permeating thiomer nanoparticles. Eur. J. Pharm. Biopharm., 2015.
137. [137] Gabor, F., Bogner, E., Weissenboeck, A., Wirth, M., The lectin–cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev. 56 (2004), 459–480.
138. [138] Zhang, N., Ping, Q.N., Huang, G.H., Xu, W.F., Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int. J. Pharm. 294 (2005), 247–259.
139. [139] Pusztai, A., Ewen, S.W., Grant, G., Brown, D.S., Stewart, J.C., Peumans, W.J., Van Damme, E.J., Bardocz, S., Antinutritive effects of wheat-germ agglutinin and other N-acetylglucosamine-specific lectins. Br. J. Nutr. 70 (1993), 313–321.
140. [140] Gabor, F., Wirth, M., Jurkovich, B., Haberl, I., Theyer, G., Walcher, G., Hamilton, G., Lectin-mediated bioadhesion: proteolytic stability and binding-characteristics of wheat germ agglutinin and Solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes. J. Control. Release 49 (1997), 27–37.
141. [141] Liu, Y., Wang, P., Sun, C., Zhao, J., Du, Y., Shi, F., Feng, N., Bioadhesion and enhanced bioavailability by wheat germ agglutinin-grafted lipid nanoparticles for oral delivery of poorly water-soluble drug bufalin. Int. J. Pharm. 419 (2011), 260–265.
142. [142] Werle, M., Makhlof, A., Takeuchi, H., Carbopol-lectin conjugate coated liposomes for oral peptide delivery. Chem. Pharm. Bull. 58 (2010), 432–434.
143. [143] Yin, Y., Chen, D., Qiao, M., Wei, X., Hu, H., Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control. Release 123 (2007), 27–38.
144. [144] Hussain, N., Jani, P., Florence, A., Enhanced oral uptake of tomato lectin conjugated nanoparticles in the rat. Pharm. Res. 14 (1997), 613–618.
145. [145] Naisbett, B., Woodley, J., The potential use of tomato lectin for oral drug delivery: 2. Mechanism of uptake in vitro. Int. J. Pharm. 110 (1994), 127–136.
146. [146] Naisbett, B., Woodley, J., The potential use of tomato lectin for oral drug delivery: 4. Immunological consequences. Int. J. Pharm. 120 (1995), 247–254.
147. [147] Loretz, B., Thaler, M., Bernkop-Schnürch, A., Role of sulfhydryl groups in transfection? A case study with chitosan–NAC nanoparticles. Bioconjug. Chem. 18 (2007), 1028–1035.
148. [148] Miller, C.R., Bondurant, B., McLean, S.D., McGovern, K.A., O'Brien, D.F., Liposome–cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37 (1998), 12875–12883.
149. [149] Lin, J., Alexander-Katz, A., Cell membranes open “doors” for cationic nanoparticles/biomolecules: insights into uptake kinetics. ACS Nano 7 (2013), 10799–10808.
150. [150] Bonengel, S., Prufert, F., Perera, G., Schauer, J., Bernkop-Schnurch, A., Polyethylene imine-6-phosphogluconic acid nanoparticles—a novel zeta potential changing system. Int. J. Pharm. 483 (2015), 19–25.
151. [151] LeCluyse, E.L., Sutton, S.C., In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement. Adv. Drug Deliv. Rev. 23 (1997), 163–183.
152. [152] Plapied, L., Duhem, N., des Rieux, A., Préat, V., Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci. 16 (2011), 228–237.
153. [153] Orci, L., Malaisse-Lagae, F., Ravazzola, M., Rouiller, D., Renold, A.E., Perrelet, A., Unger, R., A morphological basis for intercellular communication between alpha- and beta-cells in the endocrine pancreas. J. Clin. Invest. 56 (1975), 1066–1070.
154. [154] Salamat-Miller, N., Johnston, T.P., Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294 (2005), 201–216.
155. [155] Nellans, H.N., (B) Mechanisms of peptide and protein absorption: (1) paracellular intestinal transport: modulation of absorption. Adv. Drug Deliv. Rev. 7 (1991), 339–364.
156. [156] Fasano, A., Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol. 16 (1998), 152–157.
157. [157] Salama, N.N., Eddington, N.D., Fasano, A., Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58 (2006), 15–28.
158. [158] Yeh, T.-H., Hsu, L.-W., Tseng, M.T., Lee, P.-L., Sonjae, K., Ho, Y.-C., Sung, H.-W., Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 32 (2011), 6164–6173.
159. [159] Zhang, J., Zhu, X., Jin, Y., Shan, W., Huang, Y., Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles. Mol. Pharm. 11 (2014), 1520–1532.
160. [160] Sonoda, N., Furuse, M., Sasaki, H., Yonemura, S., Katahira, J., Horiguchi, Y., Tsukita, S., Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol. 147 (1999), 195–204.
161. [161] Aungst, B.J., Intestinal permeation enhancers. J. Pharm. Sci. 89 (2000), 429–442.
162. [162] Clausen, A.E., Bernkop-Schnurch, A., Thiolated carboxymethylcellulose: in vitro evaluation of its permeation enhancing effect on peptide drugs. Eur. J. Pharm. Biopharm. 51 (2001), 25–32.
163. [163] Goldberg, D.S., Ghandehari, H., Swaan, P.W., Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. Pharm. Res. 27 (2010), 1547–1557.
164. [164] Kitchens, K.M., Foraker, A.B., Kolhatkar, R.B., Swaan, P.W., Ghandehari, H., Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 24 (2007), 2138–2145.
165. [165] He, B., Lin, P., Jia, Z., Du, W., Qu, W., Yuan, L., Dai, W., Zhang, H., Wang, X., Wang, J., Zhang, X., Zhang, Q., The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. Biomaterials 34 (2013), 6082–6098.
166. [166] Bareford, L.M., Swaan, P.W., Endocytic mechanisms for targeted dug delivery. Adv. Drug Deliv. Rev. 59 (2007), 748–758.
167. [167] Zhang, X., Wu, W., Ligand-mediated active targeting for enhanced oral absorption. Drug Discov. Today 19 (2014), 898–904.
168. [168] Florence, A.T., Hillery, A.M., Hussain, N., Jani, P.U., Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target. 3 (1995), 65–70.
169. [169] Florence, A.T., Hillery, A.M., Hussain, N., Jani, P.U., Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J. Control. Release 36 (1995), 39–46.
170. [170] Pusztai, A., Ewen, S.W., Grant, G., Peumans, W.J., van Damme, E.J., Rubio, L., Bardocz, S., Relationship between survival and binding of plant lectins during small intestinal passage and their effectiveness as growth factors. Digestion 46:Suppl. 2 (1990), 308–316.
171. [171] Lochner, N., Pittner, F., Wirth, M., Gabor, F., Wheat germ agglutinin binds to the epidermal growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence. Pharm. Res. 20 (2003), 833–839.
172. [172] Wirth, M., Kneuer, C., Lehr, C.M., Gabor, F., Lectin-mediated drug delivery: discrimination between cytoadhesion and cytoinvasion and evidence for lysosomal accumulation of wheat germ agglutinin in the Caco-2 model. J. Drug Target. 10 (2002), 439–448.
173. [173] Du, W., Fan, Y., Zheng, N., He, B., Yuan, L., Zhang, H., Wang, X., Wang, J., Zhang, X., Zhang, Q., Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 34 (2013), 794–806.
174. [174] Xia, C.Q., Shen, W.C., Tyrphostin-8 enhances transferrin receptor-mediated transcytosis in Caco-2- cells and inreases hypoglycemic effect of orally administered insulin-transferrin conjugate in diabetic rats. Pharm. Res. 18 (2001), 191–195.
175. [175] Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., Langer, R., Farokhzad, O.C., Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci. Transl. Med., 5, 2013, 213ra167.
176. [176] Liu, C., Shan, W., Liu, M., Zhu, X., Xu, J., Xu, Y., Huang, Y., A novel ligand conjugated nanoparticles for oral insulin delivery. Drug Deliv., 2015, 1–11.
177. [177] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
178. [178] van der Merwe, S.M., Verhoef, J.C., Kotzé, A.F., Junginger, H.E., N-trimethyl chitosan chloride as absorption enhancer in oral peptide drug delivery. Development and characterization of minitablet and granule formulations. Eur. J. Pharm. Biopharm. 57 (2004), 85–91.
179. [179] Fan, T., Chen, C., Guo, H., Xu, J., Zhang, J., Zhu, X., Yang, Y., Zhou, Z., Li, L., Huang, Y., Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur. J. Pharm. Biopharm. 88 (2014), 518–528.
180. [180] International Transporter, C., Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa, T., Keppler, D., Kim, R.B., Lee, C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Yee, S.W., Zamek-Gliszczynski, M.J., Zhang, L., Membrane transporters in drug development. Nat. Rev. Drug Discov. 9 (2010), 215–236.
181. [181] Aungst, B.J., Absorption enhancers: applications and advances. AAPS J. 14 (2012), 10–18.
182. [182] Niu, M., Lu, Y., Hovgaard, L., Guan, P., Tan, Y., Lian, R., Qi, J., Wu, W., Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur. J. Pharm. Biopharm. 81 (2012), 265–272.
183. [183] Niu, M., Lu, Y., Hovgaard, L., Wu, W., Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int. J. Nanomedicine 6 (2011), 1155–1166.
184. [184] Ziv, E., Lior, O., Kidron, M., Absorption of protein via the intestinal wall: a quantitative model. Biochem. Pharmacol. 36 (1987), 1035–1039.
185. [185] Song, K.-H., Chung, S.-J., Shim, C.-K., Preparation and evaluation of proliposomes containing salmon calcitonin. J. Control. Release 84 (2002), 27–37.
186. [186] Zhu, S., Chen, S., Gao, Y., Guo, F., Li, F., Xie, B., Zhou, J., Zhong, H., Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec). Drug Deliv., 2015, 1–12.
187. [187] Liu, X., Liu, C., Zhang, W., Xie, C., Wei, G., Lu, W., Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int. J. Pharm. 448 (2013), 159–167.
188. [188] Varkouhi, A.K., Scholte, M., Storm, G., Haisma, H.J., Endosomal escape pathways for delivery of biologicals. J. Control. Release 151 (2011), 220–228.
189. [189] Boeckle, S., Fahrmeir, J., Roedl, W., Ogris, M., Wagner, E., Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J. Control. Release 112 (2006), 240–248.
190. [190] Meyer, M., Philipp, A., Oskuee, R., Schmidt, C., Wagner, E., Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery. J. Am. Chem. Soc. 130 (2008), 3272–3273.
191. [191] Cho, Y.W., Kim, J.D., Park, K., Polycation gene delivery systems: escape from endosomes to cytosol. J. Pharm. Pharmacol. 55 (2003), 721–734.
192. [192] Zelphati, O., Szoka, F.C. Jr., Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?. J. Control. Release 41 (1996), 99–119.
193. [193] Hafez, I.M., Cullis, P.R., Roles of lipid polymorphism in intracellular delivery. Adv. Drug Deliv. Rev. 47 (2001), 139–148.
194. [194] Wang, T., Upponi, J.R., Torchilin, V.P., Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int. J. Pharm. 427 (2012), 3–20.
195. [195] Moghimi, S.M., Symonds, P., Murray, J.C., Hunter, A.C., Debska, G., Szewczyk, A., A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol. Ther. 11 (2005), 990–995.
196. [196] Luzio, J.P., Gray, S.R., Bright, N.A., Endosome–lysosome fusion. Biochem. Soc. Trans. 38 (2010), 1413–1416.
197. [197] Luzio, J.P., Pryor, P.R., Bright, N.A., Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8 (2007), 622–632.
198. [198] Bansal, T., Akhtar, N., Jaggi, M., Khar, R.K., Talegaonkar, S., Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today 14 (2009), 1067–1074.
199. [199] Choudhuri, S., Klaassen, C.D., Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25 (2006), 231–259.
200. [200] Adachi, Y., Suzuki, H., Schinkel, A.H., Sugiyama, Y., Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol. Pharmacol. 67 (2005), 923–928.
201. [201] van de Wetering, K., Burkon, A., Feddema, W., Bot, A., de Jonge, H., Somoza, V., Borst, P., Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol. 75 (2009), 876–885.
202. [202] Didziapetris, R., Japertas, P., Avdeef, A., Petrauskas, A., Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11 (2003), 391–406.
203. [203] Hunter, J., Hirst, B.H., Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Deliv. Rev. 25 (1997), 129–157.
204. [204] Schinkel, A.H., Jonker, J.W., Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003), 3–29.
205. [205] Palmberger, T.F., Laffleur, F., Greindl, M., Bernkop-Schnürch, A., In vivo evaluation of anionic thiolated polymers as oral delivery systems for efflux pump inhibition. Int. J. Pharm. 491 (2015), 318–322.
206. [206] Bansal, T., Jaggi, M., Khar, R.K., Talegaonkar, S., Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 12 (2009), 46–78.
207. [207] Föger, F., Schmitz, T., Bernkop-Schnürch, A., In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27 (2006), 4250–4255.
208. [208] Riley, R.G., Green, K.L., Smart, J.D., Tsibouklis, J., Alf Davis, J., Hampson, F., Dettmar, P.W., Wilber, W.R., The gastrointestinal transit profile of 14C-labelled poly(acrylic acids): an in vivo study. Biomaterials 22 (2001), 1861–1867.
209. [209] Föger, F., Hoyer, H., Kafedjiiski, K., Thaurer, M., Bernkop-Schnürch, A., In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 27 (2006), 5855–5860.
210. [210] Beloqui, A., Solinis, M.A., Gascon, A.R., del Pozo-Rodriguez, A., des Rieux, A., Preat, V., Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release 166 (2013), 115–123.
211. [211] Garrigues, A., Escargueil, A.E., Orlowski, S., The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 10347–10352.
212. [212] Yunomae, K., Arima, H., Hirayama, F., Uekama, K., Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 536 (2003), 225–231.
213. [213] Barakat, S., Demeule, M., Pilorget, A., Regina, A., Gingras, D., Baggetto, L.G., Beliveau, R., Modulation of p-glycoprotein function by caveolin-1 phosphorylation. J. Neurochem. 101 (2007), 1–8.
214. [214] Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur. J. Pharm. Sci. 40 (2010), 422–429.
215. [215] Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release 140 (2009), 174–181.
216. [216] Setyawati, M.I., Tay, C.Y., Docter, D., Stauber, R.H., Leong, D.T., Understanding and exploiting nanoparticles’ intimacy with the blood vessel and blood. Chem. Soc. Rev. 44 (2015), 8174–8199.
217. [217] Walkey, C.D., Chan, W.C., Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41 (2012), 2780–2799.
218. [218] Walkey, C.D., Olsen, J.B., Guo, H., Emili, A., Chan, W.C., Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134 (2012), 2139–2147.
219. [219] Sakulkhu, U., Mahmoudi, M., Maurizi, L., Coullerez, G., Hofmann-Amtenbrink, M., Vries, M., Motazacker, M., Rezaee, F., Hofmann, H., Significance of surface charge and shell material of superparamagnetic iron oxide nanoparticle (SPION) based core/shell nanoparticles on the composition of the protein corona. Biomater. Sci. 3 (2015), 265–278.
220. [220] Ma, Z., Bai, J., Jiang, X., Monitoring of the enzymatic degradation of protein corona and evaluating the accompanying cytotoxicity of nanoparticles. ACS Appl. Mater. Interfaces, 2015.
221. [221] Liu, R., Jiang, W., Walkey, C.D., Chan, W.C., Cohen, Y., Prediction of nanoparticles–cell association based on corona proteins and physicochemical properties. Nanoscale 7 (2015), 9664–9675.
222. [222] Koshkina, O., Lang, T., Thiermann, R., Docter, D., Stauber, R.H., Secker, C., Schlaad, H., Weidner, S.M., Mohr, B.G., Maskos, M., Bertin, A., Temperature-triggered formation of a protein corona on polymer-coated nanoparticles. Langmuir, 2015.
223. [223] Docter, D., Bantz, C., Westmeier, D., Galla, H.J., Wang, Q., Kirkpatrick, J.C., Nielsen, P., Maskos, M., Stauber, R.H., The protein corona protects against size- and dose-dependent toxicity of amorphous silica nanoparticles. Beilstein J. Nanotechnol. 5 (2014), 1380–1392.
224. [224] Besinis, A., De Peralta, T., Tredwin, C.J., Handy, R.D., Review of nanomaterials in dentistry: interactions with the oral microenvironment, clinical applications, hazards, and benefits. ACS Nano 9 (2015), 2255–2289.
225. [225] Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., Landfester, K., Schild, H., Maskos, M., Knauer, S.K., Stauber, R.H., Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nano 8 (2013), 772–781.
226. [226] Monahan, F.J., McClements, D.J., German, J.B., Disulfide-mediated polymerization reactions and physical properties of heated WPI-stabilized emulsions. J. Food Sci. 61 (1996), 504–509.
227. [227] Kim, H.J., Decker, E.A., McClements, D.J., Role of postadsorption conformation changes of β-lactoglobulin on its ability to stabilize oil droplets against flocculation during heating at neutral pH. Langmuir 18 (2002), 7577–7583.
228. [228] Ulbrich, K., Knobloch, T., Kreuter, J., Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB). J. Drug Target. 19 (2011), 125–132.
229. [229] Troncoso, E., Aguilera, J.M., McClements, D.J., Influence of particle size on the in vitro digestibility of protein-coated lipid nanoparticles. J. Colloid Interface Sci. 382 (2012), 110–116.
230. [230] Fadeel, B., Garcia-Bennett, A.E., Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv. Drug Deliv. Rev. 62 (2010), 362–374.
231. [231] Torchilin, V.P., Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 64 (2012), 302–315 (Supplement).
232. [232] Hatakeyama, H., Akita, H., Harashima, H., A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev. 63 (2011), 152–160.
233. [233] Torchilin, V., Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 71 (2009), 431–444.
234. [234] Kirpotin, D., Hong, K., Mullah, N., Papahadjopoulos, D., Zalipsky, S., Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. 388 (1996), 115–118.
235. [235] Tang, J., Zhang, L., Fu, H., Kuang, Q., Gao, H., Zhang, Z., He, Q., A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes. Acta Pharm. Sin. B 4 (2014), 67–73.
236. [236] Shan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., Zhang, Z., Huang, Y., Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano 9 (2015), 2345–2356.
237. [237] Wu, W.D., Lin, S.X., Chen, X.D., Monodisperse droplet formation through a continuous jet break-up using glass nozzles operated with piezoelectric pulsation. AICHE J. 57 (2011), 1386–1392.
238. [238] Yu, F., Li, Y., Liu, C.S., Chen, Q., Wang, G.H., Guo, W., Wu, X.E., Li, D.H., Wu, W.D., Chen, X.D., Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin. Int. J. Pharm. 484 (2015), 181–191.
239. [239] Goto, T., Morishita, M., Nishimura, K., Nakanishi, M., Kato, A., Ehara, J., Takayama, K., Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm. Res. 23 (2006), 384–391.
240. [240] Ziv, E., Bendayan, M., Intestinal absorption of peptides through the enterocytes. Microsc. Res. Tech. 49 (2000), 346–352.
241. [241] Bendayan, M., Ziv, E., Gingras, D., Ben-Sasson, R., Bar-On, H., Kidron, M., Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 37 (1994), 119–126.
242. [242] Malhaire, H., Lagarce, F., Is the translational approach becoming a reality in nanomedicine?. Eur. J. Nanomed., 7, 2015.
243. [243] Malik, N., Wiwattanapatapee, R., Klopsch, R., Lorenz, K., Frey, H., Weener, J.W., Meijer, E.W., Paulus, W., Duncan, R., Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Release 65 (2000), 133–148.
244. [244] Roberts, J.C., Bhalgat, M.K., Zera, R.T., Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 30 (1996), 53–65.
245. [245] Duchene, D., Bochot, A., Yu, S.C., Pepin, C., Seiller, M., Cyclodextrins and emulsions. Int. J. Pharm. 266 (2003), 85–90.
246. [246] Hawkins, M.J., Soon-Shiong, P., Desai, N., Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60 (2008), 876–885.
247. [247] Wang, X.-Q., Zhang, Q., pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82 (2012), 219–229.
248. [248] Zhang, X.Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., Farokhzad, O.C., Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv. Drug Deliv. Rev. 64 (2012), 1363–1384.
249. [249] Bernkop-Schnürch, A., Gabor, F., Szostak, M.P., Lubitz, W., An adhesive drug delivery system based on K99-fimbriae. Eur. J. Pharm. Sci. 3 (1995), 293–299.
250. [250] Ikesue, K., Kopečkovà, P., Kopeček, J., Degradation of proteins by guinea pig intestinal enzymes. Int. J. Pharm. 95 (1993), 171–179.
251. [251] Kimura, T., Sato, K., Sugimoto, K., Tao, R., Murakami, T., Kurosaki, Y., Nakayama, T., Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats. Biol. Pharm. Bull. 19 (1996), 897–900.
252. [252] Morishita, I., Morishita, M., Takayama, K., Machida, Y., Nagai, T., Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm. 78 (1992), 9–16.
253. [253] Morishita, I., Morishita, M., Takayama, K., Machida, Y., Nagai, T., Enteral insulin delivery by microspheres in 3 different formulations using Eudragit L100 and S100. Int. J. Pharm. 91 (1993), 29–37.
254. [254] Morishita, M., Goto, T., Nakamura, K., Lowman, A.M., Takayama, K., Peppas, N.A., Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats. J. Control. Release 110 (2006), 587–594.
255. [255] Lueβen, H.L., Bohner, V., Pérard, D., Langguth, P., Verhoef, J.C., de Boer, A.G., Merkle, H.P., Junginger, H.E., Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles. Int. J. Pharm. 141 (1996), 39–52.
256. [256] Másson, M., Loftsson, T., Másson, G.s., Stefánsson, E., Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J. Control. Release 59 (1999), 107–118.
257. [257] Morishita, M., Kamei, N., Ehara, J., Isowa, K., Takayama, K., A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release 118 (2007), 177–184.
258. [258] Khafagy el, S., Morishita, M., Oral biodrug delivery using cell-penetrating peptide. Adv. Drug Deliv. Rev. 64 (2012), 531–539.
259. [259] Nielsen, E.J., Yoshida, S., Kamei, N., Iwamae, R., Khafagy el, S., Olsen, J., Rahbek, U.L., Pedersen, B.L., Takayama, K., Takeda-Morishita, M., In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J. Control. Release 189 (2014), 19–24.
260. [260] Richard, J.P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M.J., Chernomordik, L.V., Lebleu, B., Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003), 585–590.
261. [261] Morishita, M., Peppas, N.A., Is the oral route possible for peptide and protein drug delivery?. Drug Discov. Today 11 (2006), 905–910.